News

Peregrine Pharmaceuticals has received US Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies. It also includes Peregrine’s lead clinical compound, bavituximab. PS

Pfizer has exercised its option to license Flamel Technologies’ (Flamel) Medusa technology for the development of a controlled release formulation of an already-marketed therapeutic protein. Flamel is expected

Emerson Resources has formed a strategic partnership with Bio Research, to further extend its business development capabilities. The partnership leverages the expertise of industry veteran Robert Westbrook, CEO

PharmaForm, a wholly owned subsidiary of Akela Pharma has enhanced its portfolio of bioavailability enhancement solutions by adding aqueous and solvent spray drying. PharmaForm claimed that its processing

Antigenics has indicated that GlaxoSmithKline’s (GSK) Phase III malaria vaccine clinical trial, containing Antigenics’ QS-21 Stimulon adjuvant, has enrolled more than 5,000 children to date and is expected

Unilife Medical Solutions (Unilife Australia) has entered into a merger implementation agreement with Unilife Corporation (Unilife USA) to facilitate the proposed redomiciliation of the Unilife group in the

FDA has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, Shire’s enzyme replacement therapy in development for the treatment of type 1 Gaucher disease.

Sinus Dynamics has discovered a treatment for Nasal Allergies, Sinus Infections and Sinusitis by combining antibiotic and anti-inflammatory medications. The company said that it offers combined antibiotic and

Alnylam has advanced the RNAi therapeutic collaboration stage of its alliance with Roche formed in 2007. In this phase of the collaboration, the partners are expected to jointly